A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic, Scottsdale
-
-
California
-
Irvine, California, United States, 92868-4281
- UC, Irvine
-
Los Angeles, California, United States, 90095
- UCLA
-
San Francisco, California, United States, 94115
- California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic, Jacksonville
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- The Emory Clinic
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center, Landon Center on Aging
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0284
- University of Kentucky, Department of Neurology
-
-
Massachusetts
-
Charlestown, Massachusetts, United States, 02129
- Massachusetts General Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University, Syracuse
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Carolinas Medical Center
-
Durham, North Carolina, United States, 27705
- Duke University, Dept of Neurology
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence ALS Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Methodist Hospital Research Institute, Methodist Neurologic Institute
-
-
Washington
-
Centralia, Washington, United States, 98531
- Providence Saint Peter Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. A list of key criteria is listed below:
Inclusion Criteria:
- Onset of symptoms less than 3 years prior to study entry.
- Forced Vital Capacity (FVC) at least 70% of that predicted for age and height.
- Stable dose of riluzole if undergoing treatment with this agent.
- For females: Not be of childbearing potential or agree to use adequate birth control during the study.
Exclusion Criteria:
- Unstable medical condition(s) other than ALS.
- Life expectancy of less than 6 months.
- Require life-sustaining interventions for the 6 months following randomization.
- Have a tracheotomy or be using ventilatory assistance [including Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)].
- Active pulmonary disease.
- Immune modulator therapy within 12 weeks of study entry or participation in studies of other agents within the last 4 weeks prior to the randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
normal saline
|
normal saline
|
|
Experimental: Low dose NP001
Low drug dose
|
Low dose of NP001
High dose of NP001
|
|
Experimental: High dose NP001
High drug dose
|
Low dose of NP001
High dose of NP001
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the effects of NP001 on measures of clinical function
Time Frame: over 9 months
|
over 9 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and tolerability in ALS
Time Frame: duration of study
|
duration of study
|
|
Pulmonary function and biomarkers
Time Frame: over 9 months
|
over 9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert G. Miller, MD, Forbes Norris ALS Treatment and Research, California Pacific Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NP001-10-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.